BioCryst Earnings Call Highlights Profits, Pipeline Momentum
BioCryst Pharmaceuticals ((BCRX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioCryst Pharmaceuticals’ latest earnings call painted a broadly optimistic picture, with management highlighting record profitability, strong ORLADEYO growth, and a fortified balance sheet supporting an ambitious R&D agenda. While executives acknowledged near‑term headwinds from seasonal dynamics, higher 2026 R&D spending, and regulatory timing risks, they argued these are manageable against the backdrop of robust clinical data and scalable commercial execution.
Record ORLADEYO Full‑Year Revenue
BioCryst delivered full‑year 2025 ORLADEYO revenue of $601.8 million, a 38% year‑over‑year increase and 43% growth when excluding the divested European business. Management framed this performance as evidence that ORLADEYO remains a powerful growth engine in hereditary angioedema, even after shedding a non‑core geography.
Strong Overall Revenue and Profitability
Total non‑GAAP revenue in 2025 climbed 45% year over year, with ORLADEYO contributing roughly $169 million of incremental non‑GAAP revenue, or about 43% growth. Non‑GAAP operating profit surged to $214 million, up 198% from the prior year and the highest in the company’s history, underscoring operating leverage as the franchise scales.
Robust Balance Sheet and Financing Optionality
The company ended 2025 with $337.5 million in cash and investments, providing a solid liquidity cushion as it advances late‑stage programs. A $400 million financing facility with Blackstone Life Sciences adds further optionality, giving BioCryst flexibility to fund development, manage risk, and potentially accelerate strategic initiatives without immediate equity dilution.
Pediatric Approval for ORLADEYO Pellets
The December 2025 FDA approval of ORLADEYO pellets for children aged 2 to under 12 marks a strategic expansion of the franchise into younger patients. Management has baked only a small pediatric contribution into 2026 guidance, but emphasized the long‑term upside as diagnosis improves and treatment rates in children move closer to adult levels.
Navenibart Clinical Efficacy and Development Progress
Navenibart’s Phase II ALPHA‑SOLAR data showed striking efficacy, with mean attack rate reductions of 92% on an every‑three‑month schedule and 90% on an every‑six‑month schedule. Patients saw mean attack rates fall from 2.23 per month to 0.16, translating to fewer than two attacks per year, while median attack reductions reached 97%, supporting its potential as a best‑in‑class prophylactic.
Clear Regulatory & Development Timeline for Navenibart
BioCryst outlined a structured path forward for navenibart, targeting completion of the pivotal Phase III enrollment of 145 patients around mid‑2026. The company plans to submit a biologics license application by the end of 2027, driven largely by the need for 12 months of safety data, with an eye toward potential U.S. approval in late 2028 if timelines and regulatory interactions remain on track.
BCX17725 Early‑Stage Results and Patient Study Initiation
In early development, BCX17725’s Phase I data showed the drug was safe and well tolerated in healthy volunteers, with linear exposure, epidermal distribution, and a half‑life of roughly 12 to 19 days. BioCryst is prioritizing patient cohorts in Part 4 of the study, enrolling up to 12 patients to generate proof‑of‑concept data by year‑end 2026, which could support pipeline diversification beyond ORLADEYO and navenibart.
Commercial Execution and Patient Persistence
Management highlighted strong real‑world persistence on ORLADEYO, noting pivotal data where just over half of starters stayed on therapy for two years with a 91% attack reduction. In clinical practice, about 60% of patients remain on treatment after 12 months and nearly half of U.S. patients who have tried ORLADEYO over the past five years are still on therapy, supporting durable revenue and a sales and marketing return of roughly four times net sales.
Conservative, Disciplined Financial Guidance
For 2026, BioCryst guided ORLADEYO revenues to a range of $625 million to $645 million, implying about 13% growth versus 2025 when adjusted for Europe. Non‑GAAP operating expenses are expected at $450 million to $470 million, including costs from the Astria integration, with management stressing disciplined R&D spending and rigorous capital allocation as late‑stage programs peak.
European Business Divestiture and Impact
The sale of the European ORLADEYO business, described as loss‑making, reduces reported revenue but improves the profitability mix and refocuses resources on higher‑margin markets. With the U.S. now representing more than 90% of sales, investors must weigh the benefit of stronger margins against the reduction in geographic diversification and increased dependence on one market.
Q1 Reauthorization Headwind
Executives cautioned that first‑quarter 2026 revenue is likely to dip slightly versus the fourth quarter because of annual payer reauthorizations. During this period, BioCryst expects higher co‑pay assistance, more free product, and the absence of the prior year’s Medicare policy tailwind to temporarily pressure reported sales before volumes normalize and rebound in the second quarter.
Near‑Term R&D Cost Increase
R&D spending is set to rise in 2026 as BioCryst completes the navenibart Phase III program and undertakes biologics license application‑enabling chemistry, manufacturing, and controls work. Management framed this as a deliberate, time‑bounded investment, guiding that R&D intensity should ease beyond 2026 once critical late‑stage milestones are met and the pipeline transitions toward potential commercialization.
Pediatric Uptake Uncertainty
Despite the new pediatric approval, executives acknowledged uncertainty around how quickly children aged 2 to under 12 will start treatment, given under‑diagnosis and lower treatment rates versus adults. As a result, the company has only modest pediatric volumes in its 2026 forecast, leaving room for upside if awareness campaigns, diagnosis rates, and physician comfort with the pellets accelerate adoption.
Predictability of ORLADEYO Super Responders
The company noted there are no reliable predictors for which patients will become ORLADEYO “super responders,” who experience exceptionally large attack reductions. Physicians and patients generally need three to six months on therapy to gauge response, which introduces some element of trial‑and‑error and potential early churn but also allows strong responders to be identified and retained over the long term.
Development and Regulatory Timing Risks
BioCryst emphasized that navenibart timelines are still subject to operational and regulatory variables, including the pace of enrollment and the requirement for a full year of safety follow‑up on the last patient. The biologics license application schedule also depends on alignment with regulators, leaving the late‑2028 approval goal exposed to potential delays from slower recruitment or shifting agency review timing.
Guidance and Longer‑Term Outlook
Looking ahead, management’s 2026 guide calls for mid‑teens ORLADEYO growth off an already elevated base, underpinned by price, patient adds, and a small pediatric contribution. BioCryst believes it can reach $1 billion in peak ORLADEYO revenue by 2029 with roughly 150 net new patients per year, supported by strong cash reserves, the $400 million Blackstone facility, and progressing timelines toward a navenibart filing by 2027 and potential approval in 2028.
BioCryst’s call balanced near‑term caution with long‑term confidence, anchored by record non‑GAAP operating profit and compelling efficacy data from its late‑stage pipeline. For investors, the story now hinges on steady ORLADEYO execution through seasonal and reimbursement noise, disciplined management of elevated 2026 R&D, and timely advancement of navenibart and BCX17725 to sustain growth beyond the current flagship franchise.
